Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

AnaptysBio, Inc. (ANAB)

24.11   -0.3 (-1.23%) 01-27 16:00
Open: 24.41 Pre. Close: 24.41
High: 25.01 Low: 23.83
Volume: 672,314 Market Cap: 685(M)

Technical analysis

as of: 2023-01-27 4:42:29 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 32.77     One year: 37.88
Support: Support1: 20.97    Support2: 17.45
Resistance: Resistance1: 28.05    Resistance2: 32.43
Pivot: 24.08
Moving Average: MA(5): 24.74     MA(20): 25.62
MA(100): 27.1     MA(250): 25.28
MACD: MACD(12,26): -1     Signal(9): -1
Stochastic oscillator: %K(14,3): 38.6     %D(3): 39.6
RSI: RSI(14): 41.9
52-week: High: 32.43  Low: 18.2
Average Vol(K): 3-Month: 281 (K)  10-Days: 422 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ANAB ] has closed below upper band by 49.6%. Bollinger Bands are 18.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 25.06 - 25.21 25.21 - 25.33
Low: 23.48 - 23.67 23.67 - 23.82
Close: 23.85 - 24.14 24.14 - 24.36

Company Description

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Headline News

Sun, 29 Jan 2023
StockNews.com Upgrades AnaptysBio (NASDAQ:ANAB) to "Hold" - MarketBeat

Sun, 29 Jan 2023
Glendale police crime lab accredited through ANAB | News ... - Glendale Star

Sat, 28 Jan 2023
AnaptysBio Inc. (NASDAQ:ANAB) -3.56% Down Over Last Week ... - Marketing Sentinel

Fri, 27 Jan 2023
SG Americas Securities LLC sells 4,353 AnaptysBio, Inc. shares ... - Best Stocks

Thu, 26 Jan 2023
SheerID Achieves Updated Information Security-Based ISO/IEC Certification Status - Yahoo Finance

Mon, 16 Jan 2023
Why The AnaptysBio Stock Increased 14.35% (ANAB) - Pulse 2.0

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 28 (M)
% Held by Insiders 1.42e+007 (%)
% Held by Institutions 0.3 (%)
Shares Short 5,540 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.1648e+008
EPS Est Next Qtl -0.67
EPS Est This Year -2
EPS Est Next Year -3.06
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -2
Return on Assets (ttm) 608.8
Return on Equity (ttm) -14.1
Qtrly Rev. Growth 4.49e+006
Gross Profit (p.s.) -4690
Sales Per Share -2039.5
EBITDA (p.s.) -1.766e+009
Qtrly Earnings Growth -2.8
Operating Cash Flow 0 (M)
Levered Free Cash Flow -88 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow -0.05

Stock Dividends

Dividend 0
Forward Dividend 5.46e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.